infigratinib
bridgebio pharmaceutical
['urothelial carcinoma', ' uc,(-ucsd),(-ucsf),', 'proof 302', 'infigratinib', 'bladder', 'urothelial']
fgfr3 alt in proof 302: ph 3 trial of infigratinib as adj rx in pts with invasive urothelial carcinoma #asco23 n=617 screened 30% alterations in fgfr 1-4 genes 19% fgfr3 alterations: 30% utuc, 13% of bladder uc, 9% of unknown tumor site trial 
Uro Onc @GACancerCenter | Assoc Prof, Resident PD, and Ronald W. Lewis, MD Chair of Uro Educ @mcg_urology | #mentalhealth research | @urotoday Contributor